Stock 300878 ZHEJIANG WECOME PHARMACEUTICAL COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Zhejiang Wecome Pharmaceutical Company Limited

Equities

300878

CNE1000047P9

End-of-day quote Shenzhen S.E.
Other stock markets
 18:00:00 2024-06-06 EDT 		5-day change 1st Jan Change
15.07 CNY +2.87% Intraday chart for Zhejiang Wecome Pharmaceutical Company Limited -7.20% -40.60%
04-28 Zhejiang Wecome Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-19 Zhejiang Wecome Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Zhejiang Wecome Pharmaceutical Company Limited Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 29 May 2024
CI
Zhejiang Wecome Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Zhejiang Wecome Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Tranche Update on Zhejiang Wecome Pharmaceutical Company Limited's Equity Buyback Plan announced on February 7, 2024.
CI
Zhejiang Wecome Pharmaceutical Company Limited's Equity Buyback announced on February 7, 2024, has closed with 2,739,026 shares, representing 1.89% for CNY 50 million.
CI
Zhejiang Wecome Pharmaceutical Company Limited announces an Equity Buyback for CNY 50 million worth of its shares.
CI
Zhejiang Wecome Pharmaceutical Company Limited authorizes a Buyback Plan.
CI
Zhejiang Wecome Pharmaceutical Company Limited Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Zhejiang Wecome Pharmaceutical Company Limited Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Zhejiang Wecome Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Zhejiang Wecome Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Zhejiang Wecome Pharmaceutical Company Limited Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Zhejiang Wecome Pharmaceutical Company Limited Reports Earnings Results for the Half Year Ended June 30, 2022
CI
Zhejiang Wecome Pharmaceutical Company Limited Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2021, Payable on 17 June 2022
CI
Zhejiang Wecome Pharmaceutical Company Limited Approved Cash Dividend for the Year 2021
CI
Zhejiang Wecome Pharmaceutical Company Limited Proposes Final Cash Dividend for the Year 2021
CI
Zhejiang Wecome Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2021
CI
Zhejiang Wecome Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
LBX Pharmacy Chain Joint Stock Company singed an Asset Purchase Agreement to acquire a 71.9% stake in Hunan Huairen Great Health Industry Development Co., Ltd. from group of sellers for CNY 1.6 billion.
CI
Zhejiang Wecome Pharmaceutical Company Limited Reports Earnings Results for the Nine Months Ended September 30, 2021
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 300878 Stock
  4. News Zhejiang Wecome Pharmaceutical Company Limited
  5. Highlights